NEW YORK (360Dx) — Sienna Cancer Diagnostics said today that it has signed an agreement making Mediwell a non-exclusive distributor of its bladder cancer diagnostic in Singapore.
Sienna's in vitro diagnostic is designed to detect the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer alongside standard urine cytology testing. Under the terms of the deal, Mediwell will offer the test to pathology labs and hospitals in Singapore, as well as be responsible for securing its approval in the country. Sienna will provide training to Singapore-based Mediwell sales, marketing, and technical support staff ahead of product launch.
Additional terms were not disclosed.
Earlier this year, August, Melbourne, Australia-based Sienna inked a distribution agreement for its bladder cancer test in South Korea with Mirax. And last year, it signed on Shaanxi GaoYuan In Vitro Diagnostic Reagents as the exclusive distributor of the test in mainland China.